US2015337389A1PendingUtilityA1

Use Of Genetic Modifications In Human Gene CHK1 Which Codes For Checkpoint Kinase 1

43
Assignee: UNI DUISBURG ESSENPriority: Nov 17, 2006Filed: May 21, 2015Published: Nov 26, 2015
Est. expiryNov 17, 2026(~0.3 yrs left)· nominal 20-yr term from priority
Inventors:Kathrin RiemannWinfried Siffert
C12Q 2600/118C12Q 1/6886C12Q 2600/112C12Q 2600/156C12Q 2600/106C12Q 1/6883C12Q 2600/172
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position −1143 in the promoter of CHK1, of thymine for cytosine in position −1400, a substitution of cytosine for thymine in position −1453 or an insertion of one cytosine in position −1454 and the genetic modifications being detected individually or in any combinations by way of known methods.

Claims

exact text as granted — not AI-modified
1 . An in vitro method for predicting disease risks, progression of disease risks, progression of diseases, drug risks, success of treatment and for finding drag targets, characterized by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23. 
     
     
         2 . The method according to  claim 1 , characterized by looking for a polymorphism (−1143) G>T in a patient sample. 
     
     
         3 . The method according to  claim 1 , characterized by looking for a polymorphism (−1400) C>T in a patient sample. 
     
     
         4 . The method according to  claim 1 , characterized by looking for a polymorphism (−1453) T>C in a patient sample. 
     
     
         5 . The method according to  claim 1 , characterized by looking for a polymorphism (−1454) insC in a patient sample. 
     
     
         6 . The method according to  claim 1 , characterized by looking for one, two, three, or four of the polymorphisms (−1143) G>T, (−1400) C>T, (−1453) T>C and (−1154) insC in a patient sample. 
     
     
         7 . The method according to  claim 1 , characterized in that the disease is a cancer. 
     
     
         8 . The method according to  claim 1 , characterized in that the treatment is one with cancer therapeutic agents or a physical treatment of cancer. 
     
     
         9 . The method according to  claim 1 , characterized in that the drugs or cancer therapeutic agents are inhibitors of checkpoint kinase 1.

Join the waitlist — get patent alerts

Track US2015337389A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.